IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA PITTSBURGH DIVISION

WILLIAM L. BELL, JR.,)) ELECTRONICALLY FILED
Plaintiff,) Case No. 2:17-cv-01153-JFC
v.))
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; and ELI LILLY & COMPANY,	JURY TRIAL DEMANDED))))))))
Defendants.	,)))

DEFENDANTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY'S MOTION TO DISMISS PLAINTIFF'S FIRST AMENDED COMPLAINT

Pursuant to Federal Rules of Civil Procedure 8(a), 9(b), and 12(b)(6), Defendants

Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI") and Eli Lilly and Company ("Lilly")

(together, "Defendants")¹ submit this Motion to Dismiss Plaintiff's First Amended Complaint

("FAC") for failure to state a claim upon which relief can be granted.

Plaintiff's FAC should be dismissed in its entirety for two reasons. *First*, Plaintiff's failure to warn and design defect claims are preempted by federal law, because Defendants could not have changed the Jardiance label or redesigned Jardiance without prior permission from the

¹ As of the date of this filing, Defendants Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim International GmbH have not been served in this action.

U.S. Food and Drug Administration. *Second*, Plaintiff's FAC remains laden with conclusory allegations that are insufficient to meet federal pleading standards, despite direction from this Court to include factual allegations.

WHEREFORE, for these reasons and as more fully set forth in the Memorandum in Support filed contemporaneously with this Motion, Plaintiff's First Amended Complaint should be dismissed in its entirety. A proposed Order is attached.

Dated: March 22, 2017 Respectfully submitted,

/s/ Wendy West Feinstein

Wendy West Feinstein (PA86698) wendy.feinstein@morganlewis.com Morgan, Lewis & Bockius LLP One Oxford Centre Thirty-Second Floor Pittsburgh, PA 15219

Telephone: (412) 560-7455 Facsimile: (412) 560-7001

Heidi Levine (*pro hac vice*) hlevine@sidley.com SIDLEY AUSTIN LLP 787 7th Avenue New York, NY 10019 Telephone: (212) 839-5300 Facsimile: (212) 839-5599

Elizabeth Curtin (pro hac vice) ecurtin@sidley.com SIDLEY AUSTIN LLP One South Dearborn Street Chicago, IL 60603 Telephone: (312) 853-7000

Facsimile: (312) 853-7036

Attorneys for Defendant Boehringer Ingelheim Pharmaceuticals, Inc.

AND

John C. Hansberry (PA74721) hansberryj@pepperlaw.com PEPPER HAMILTON LLP 500 Grant Street Suite 5000 Pittsburgh, PA 15219-2507 Telephone: 412-454-5051

Barry H. Boise (pro hac vice) (PA63125) boiseb@pepperlaw.com PEPPER HAMILTON LLP 3000 Two Logan Square Eighteenth and Arch Streets

Philadelphia, PA 19103-4000 Telephone: (215) 981-4000 Facsimile: (215) 981-4750

Attorney for Defendant Eli Lilly and Company

CERTIFICATE OF SERVICE

I certify that on March 22, 2017, the foregoing was electronically filed with the Clerk of the Court using the CM/ECF system, which will send notification of such filing to all registered users, including the below-listed counsel of record:

Justin J. Hawal, Esq. DiCello Levitt & Casey LLC 7556 Mentor Avenue Mentor, OH 44060 jhawal@dlcfirm.com

Levi M. Plesset Milstein Adelman Jackson Fairchild & Wade LLP 10250 Constellation Blvd., Suite 1400 Los Angeles, CA 90067 lplesset@mjfwlaw.com

Attorneys for Plaintiff

/s/ Wendy West Feinstein

Attorney for Defendant Boehringer Ingelheim Pharmaceuticals, Inc.